newsfilter
← Earnings
Earnings Releases·

Cogent Biosciences — Third Quarter 2026 Earnings Summary

  • Cash and marketable securities totaled $791.1 million as of September 30, 2026, down from $792.3 million in June 2026, with a net loss of $111.4 million for the quarter compared to $80.9 million in the prior year period.
  • Operating expenses increased significantly year-over-year, with R&D rising to $75.1 million and G&A surging to $42.1 million, contributing to a nine-month net loss of $305.2 million versus $226.4 million in 2025.
  • The company expects its cash balance to fund operations and capital expenditures into late 2028, extending past all three pending PDUFA action dates for bezuclastinib scheduled for November 2026, December 2026, and June 2027.
  • Strategic progress includes preparing for the commercial launch of bezuclastinib in GIST, FDA acceptance of the NDA for AdvSM, and plans to submit IND applications for JAK2 and KRAS programs in Q4 2026.
Company
COGENT BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology